Claudin-5 Levels in Methamphetamine Users with and without Psychosis and Healthy Controls
DOI:
https://doi.org/10.58600/eurjther3006Keywords:
blood-brain barrier, claudin-5, methamphetamine, methamphetamine-induced psychosis, methamphetamine use disorderAbstract
Objective: The increasing prevalence of amphetamine/methamphetamine (MA) use is a global problem. Methamphetamine Induced Psychosis (MIP) causes more serious problems, increased burden on health services and has a worse prognosis than methamphetamine use disorder (MUD). In our study, we aimed to measure and compare claudin-5 levels in patients diagnosed with MUD and MIP according to DSM-5 and a healthy control group.
Methods: A total of 68 people, including 24 patients diagnosed with MUD, 20 patients diagnosed with MIP and 24 healthy controls, who met the inclusion/exclusion criteria were included in our study. Addiction Profile Index Short Form (API), Positive and Negative Syndrome Scale (PANSS) and sociodemographic data form were applied to the whole sample. Serum claudin-5 levels of the participants were measured by the ELISA method.
Results: Claudin-5 level did not show a statistically significant difference between the MUD and the control group (p>0.050). Claudin-5 levels were statistically significantly different between the MUD and MIP group (p<0.050) and between the MIP and control group (p<0.001). In the correlation analysis, a moderate negative correlation was found between claudin-5 and recent daily use in the MUD group (r=-0.535, p<0.010).
Conclusion: To the best of our knowledge, our study is the first study in which the claudin-5 level was evaluated in patients diagnosed with MUD and MIP. Our results may contribute to the development of specific diagnostic markers for MIP, the investigation of treatment options, and the identification of biological markers predisposing to psychosis.
References
[1] United Nations Office on Drugs and Crime (2019) World Drug Report 2019. United Nations publication, Sales No. E.19.XI.8. United Nations Office on Drugs and Crime, Vienna. https://doi.org/10.1016/j.scijus.2019.03.005
[2] Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ (2005) Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry. 13:141–154. https://doi.org/10.1080/10673220591003605
[3] McKetin R, Gardner J, Baker AL, Dawe S, Ali R, Voce A, Leach LS, Lubman DI (2016) Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Res. 238:166–171. https://doi.org/10.1016/j.psychres.2016.02.038
[4] McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction. 101:1473–1478. https://doi.org/10.1111/j.1360-0443.2006.01496.x
[5] Sara G, Burgess P, Malhi G, Whiteford H (2011) Amphetamine availability and admissions for psychosis in New South Wales, 2001–2009. Aust. N. Z. J. Psychiatry. 45:317–324. https://doi.org/10.3109/00048674.2010.547455
[6] Hsieh JH, Stein DJ, Howells FM (2014) The neurobiology of methamphetamine induced psychosis. Front. Hum. Neurosci. 8:537. https://doi.org/10.3389/fnhum.2014.00537
[7] Wearne TA, Cornish JL (2018) A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front. Psychiatry. 9:491. https://doi.org/10.3389/fpsyt.2018.00491
[8] Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V (2017) Methamphetamine: effects on the brain, gut and immune system. Pharmacol. Res. 120:60–67. https://doi.org/10.1016/j.phrs.2017.03.009
[9] Northrop NA, Yamamoto BK (2015) Methamphetamine effects on blood-brain barrier structure and function. Front. Neurosci. 9:69. https://doi.org/10.3389/fnins.2015.00069
[10] Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice. J. Cell Biol. 161:653–660. https://doi.org/10.1083/jcb.200302070
[11] Sun ZY, Wei J, Xie L, Shen Y, Liu SZ, Ju GZ, Shi JP, Yu YQ, Zhang X, Xu Q, Hemmings GP (2004) The CLDN5 locus may be involved in the vulnerability to schizophrenia. Eur. Psychiatry. 19:354–357. https://doi.org/10.1016/j.eurpsy.2004.06.007
[12] Ishiguro H, Imai K, Koga M, Horiuchi Y, Inada T, Iwata N, Ozaki, N, Ujike H,Itokawa M,Kunugi H,Sasaki T,Watanabe Y, Someya T, Arinami T (2008) Replication study for associations between polymorphisms in the CLDN5 and DGCR2 genes in the 22q11 deletion syndrome region and schizophrenia. Psychiatr. Genet. 18:255–256. https://doi.org/10.1097/YPG.0b013e328306c7dc
[13] Omidinia E, Mazar FM, Shahamati P, Kianmehr A, Mohammadi HS (2014) Polymorphism of the CLDN5 gene and schizophrenia in an Iranian population. Iran. J. Public Health. 43:79.
[14] Işık Ü, Aydoğan Avşar P, Aktepe E, Doğuç DK, Kılıç F, Büyükbayram Hİ (2020) Serum zonulin and claudin-5 levels in children with obsessive–compulsive disorder. Nord. J. Psychiatry. 74:346–351. https://doi.org/10.1080/08039488.2020.1715474
[15] Keaney J, Walsh DM, O’Malley T, Hudson N, Crosbie DE, Loftus T, Sheehan F, McDaid J, Humphries MM, Callanan JJ, Brett FM, Farrell MA, Humphries P, Campbell M (2015) Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier. Sci. Adv. 1:e1500472. https://doi.org/10.1126/sciadv.1500472
[16] Kılıç F, Işık Ü, Demirdaş A, Doğuç DK, Bozkurt M (2020) Serum zonulin and claudin-5 levels in patients with bipolar disorder. J. Affect. Disord. 266:37–42. https://doi.org/10.1016/j.jad.2020.01.117
[17] Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, Takahashi A, Flanigan ME, Aleyasin H, LeClair KB, Janssen WG, Labonté B, Parise EM, Lorsch ZS, Golden SA, Heshmati M, Tamminga C, Turecki G, Campbell M, Fayad ZA, Tang CY, Merad M, Russo SJ (2017) Social stress induces neurovascular pathology promoting depression. Nat. Neurosci. 20:1752–1760. https://doi.org/10.1038/s41593-017-0010-3
[18] Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner H (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood–CSF barrier dysfunction. J. Psychiatr. Res. 44:321–330. https://doi.org/10.1016/j.jpsychires.2009.08.008
[19] Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ (2018) The blood–brain barrier in psychosis. Lancet Psychiatry. 5:79–92. https://doi.org/10.1016/j.jpsychires.2009.08.008
[20] Ögel K, Güneş R, Koç C, Görücü S, Başabak A (2015) Development of the short form of the addiction profile index (BAPI) scale, validity and reliability study. Addiction. 16:175–181.
[21] Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:261–276. https://doi.org/10.1093/schbul/13.2.261
[22] Kostakoğlu A, Batur S, Tiryaki A, Göğüş A (1999) Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale. Turk. J. Psychol. 14.
[23] Martins T, Baptista S, Gonçalves J, Leal E, Milhazes N, Borges F, Ribeiro CF, Quintela O, Lendoiro E, Rivadulla ML, Ambrósio AF, Silva AP (2011) Methamphetamine transiently increases the blood–brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 1411:28–40. https://doi.org/10.1016/j.brainres.2011.07.013
[24] Stamatovic SM, Keep RF, Andjelkovic AV (2011) Tracing the endocytosis of claudin-5 in brain endothelial cells. In: Claudins: Methods and Protocols. pp 303–320.
[25] Yang Z, Huang C, Wu Y, Chen B, Zhang W, Zhang J (2019) Autophagy protects the blood-brain barrier through regulating the dynamic of claudin-5 in short-term starvation. Front. Physiol. 10:2. https://doi.org/10.3389/fphys.2019.00002
[26] Wang L, Li Z, Zhang X, Wang S, Zhu C, Miao J, Chen L, Cui L, Qiao H (2014) Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-κB, TNF-α and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability. Neurochem. Res. 39:97–106. https://doi.org/10.1007/s11064-013-1194-x
[27] Patel JP, Frey BN (2015) Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder? Neural Plast. 2015. https://doi.org/10.1155/2015/708306
[28] Greene C, Hanley N, Campbell M (2020) Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. Transl. Psychiatry. 10:373. https://doi.org/10.1038/s41398-020-01054-3
[29] Wu H, Wang J, Teng T, Yin B, He Y, Jiang Y, Liu X, Yu Y (2023) Biomarkers of intestinal permeability and blood-brain barrier permeability in adolescents with major depressive disorder. J. Affect. Disord. 323:659–666. https://doi.org/10.1016/j.jad.2022.11.058
[30] Greene C, Kealy J, Humphries M, Gong Y, Hou J, Hudson N, Cassidy LM Martiniano R, Shashi V, Hooper SR, Grant GA, Kenna PF, Norris K, Callaghan CK, Islam MdN, O’Mara SM, Najda Z, Campbell SG, Pachter JS, Thomas J, Williams NM, Humphries P, Murphy KC, Campbell M (2018) Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol. Psychiatry. 23:2156–2166. https://doi.org/10.1038/mp.2017.156
[31] Usta A, Kılıç F, Demirdaş A, Işık Ü, Doğuç DK, Bozkurt M (2021) Serum zonulin and claudin-5 levels in patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 271:767–773. https://doi.org/10.1007/s00406-020-01152-9
[32] Nishiura K, Ichikawa-Tomikawa N, Sugimoto K, Kunii Y, Kashiwagi K, Tanaka M, Yokoyama Y, Hino M, Sugino T, Yabe H, Takahashi H, Kakita A, Imura T , Chiba H(2017) PKA activation and endothelial claudin-5 breakdown in the schizophrenic prefrontal cortex. Oncotarget. 8:93382. https://doi.org/10.18632/oncotarget.21850
[33] Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, Kelly DL, Cascella N, Fasano A (2016) Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol. Autism. 7:1–17. https://doi.org/10.1186/s13229-016-0110-z
[34] Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, Dykstra H, Weksler BB, Romero IA, Couraud PO, Persidsky Y (2009) Methamphetamine disrupts blood–brain barrier function by induction of oxidative stress in brain endothelial cells. J. Cereb. Blood Flow Metab. 29:1933–1945. https://doi.org/10.1038/jcbfm.2009.112
Downloads
Published
How to Cite
License
Copyright (c) 2026 Bahadır Demir, Esra Aslan, Şengül Şahin, Seyithan Taysi, Muhammet Sancaktar, Gülçin Elboğa, Abdurrahman Altındağ
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
